Visum Prius Ltd.

To compare the differences in absorption extent and rate of upadacitinib extended-release tablets (15 mg) produced by Huayi Taikang Pharmaceutical Co., Ltd. and upadacitinib extended-release tablets (15 mg, trade name: RINVOQ®) certified by AbbVie Deutschland GmbH & Co. KG in healthy Chinese adult subjects under fasting and fed dosing conditions, evaluate the bioequivalence of the two oral preparations under fasting and fed conditions, and evaluate the safety of upadacitinib extended-release tablets (15 mg) produced by Huayi Taikang Pharmaceutical Co., Ltd.

This study examined the oral administration of a single dose of Bripipiprazole orally disintegrating tablets (test preparation, specification: 2 mg) produced by Huayitakang Pharmaceutical Co., Ltd. or Otsuka Pharmaceutical Co., Ltd. under fasting conditions to healthy subjects. Pharmacokinetic characteristics of certified bripipiprazole orally disintegrating tablets (reference preparation, trade name: Rexulti® OD Tablets, strength: 2 mg), to evaluate the bioequivalence and safety of the two preparations, this test preparation Provide basis for registration application.

In accordance with the relevant provisions of bioequivalence tests, trazodone hydrochloride tablets (trade name: RESLIN, specification: 50 mg) of which Olganon Co., Ltd. is the licensee was selected as the reference preparation, and a human bioequivalence study of postprandial administration was conducted on the test preparation trazodone hydrochloride tablets (specification: 50 mg) produced and provided by Huayi Taikang Pharmaceutical Co., Ltd. to compare whether the absorption rate and degree of the drug in the test preparation were within an acceptable range with those of the reference preparation, and to evaluate the bioequivalence of the two preparations under postprandial administration conditions.